Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
In the first month of 2022, eight IPOs raised $1.7 billion, mostly tech and healthcare. Private equity giant TPG headlined the month, followed by semiconductor play Credo Technology; the other six were either biotechs or micro-caps. Market conditions weighed on...read more
The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Nine IPOs and three SPACs submitted initial filings. CinCor Pharma (CINC) upsized and priced at the midpoint to raise $194...read more
Vigil Neuroscience, a Phase 1 biotech developing antibody therapies for neurodegenerative diseases, raised $98 million by offering 7 million shares at $14, below the range of $15 to $17. The company is addressing microglial dysfunction, which has been...read more
Biotech IPOs struggle to tread water amid challenging market conditions
Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
Renaissance Capital's January IPO Market Update
In the first month of 2022, eight IPOs raised $1.7 billion, mostly tech and healthcare. Private equity giant TPG headlined the month, followed by semiconductor play Credo Technology; the other six were either biotechs or micro-caps. Market conditions weighed on...read more
US IPO Weekly Recap: Biotechs ring in the new year in a 4 IPO week
The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Nine IPOs and three SPACs submitted initial filings. CinCor Pharma (CINC) upsized and priced at the midpoint to raise $194...read more
Neurodegenerative disease biotech Vigil Neuroscience prices IPO at $14, below the range
Vigil Neuroscience, a Phase 1 biotech developing antibody therapies for neurodegenerative diseases, raised $98 million by offering 7 million shares at $14, below the range of $15 to $17. The company is addressing microglial dysfunction, which has been...read more